Title:
Inhibiting GSK3 to Preserve Musculoskeletal and Cognitive Health during Spaceflight
Agreement Number:
21HLSRM01
Agreement Value:
$150,000.00
Agreement Date:
Mar 29, 2022 - Jul 1, 2025
Description:
Canada has committed efforts to push humanity further into the solar system beyond the International Space Station to more distant destinations like the Moon and Mars. However, travelling with the astronauts on these longer-duration missions are risks for muscle loss and weakness, bone fragility and cognitive decline, all of which will compromise astronaut well-being and the mission at hand. This research seeks to determine whether stopping an enzyme called glycogen synthase kinase 3 can slow the functional decline of muscles, bone, and brain not only in space but also here on Earth, providing novel therapeutic strategies for human health.
Organization:
Canadian Space Agency
Expected Results:
The Research component of the program provides financial support to organizations to conduct space related research and development in priority areas. It will support targeted knowledge development and innovation to sustain and enhance the Canadian capacity to use space to address national needs and priorities in the future.
Location:
Saint-Catharines, Ontario, CA L2S 3A1
Reference Number:
003-2021-2022-Q4-00064
Report Type:
Grants and Contributions
Amendment Date
Jul 30, 2025
Recipient's Legal Name:
Brock University
Program:
Class Grant and Contribution Program to Support Research, Awareness and Learning in Space Science and Technology
Program Purpose:
This program supports knowledge development and innovation in the CSA's priority areas while increasing the awareness and participation of Canadians in space-related disciplines and activities.
The Research Component aims to support the development of science and technology; foster the continual development of a critical mass of researchers and highly qualified people in Canada; and support information gathering and space-related studies and research pertaining to Canadian Space Agency priorities.